Matches 1 - 50 out of 309 1 2 3 4 5 6 7 >
Match Document Document Title
7560483 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof  
The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require...
7534766 Glucuronide metabolites and epimers thereof of tigecycline  
A glucuronide metabolite of tigecycline, and its corresponding epimer, have been identified in humans treated with tigecycline. Mass spectral data have been used to identify these structures.
7485707 Thermally stable crystalline epirubicin hydrochloride and method of making the same  
A crystalline form of epirubicin hydrochloride, named herein as “type II” crystalline epirubicin hydrochloride, has excellent thermal stability. Type II crystalline epirubicin hydrochloride has...
7445764 Carrier-drug conjugate  
The invention relates to a carrier-drug conjugate comprising a carrier containing a polypeptide sequence having one or several cysteine radicals and a pharmacon containing a pharmaceutical and/or...
7402556 Prodrugs activated by plasmin and their use in cancer chemotherapy  
The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or...
7388083 Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics  
A method of synthesizing R1, R2-substituted-4′ (ax. or eq.)-OH anthracyclines and their corresponding salts of Formula (1) from daunorubicin or N-Trifluoroacetyl-4-R1-derivatives of daunorubicin,...
7345023 Treatment of hyperproliferative conditions of body surfaces  
The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal...
7244829 Compositions and processes for preparing 13-deoxy-anthracyclines  
13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines...
7153946 Molecular conjugates for use in treatment of cancer  
A molecular conjugate is provided having the formula: wherein R 1 is a de-hydroxyl or de-amino moiety respectively of a hydroxyl-bearing or amino-bearing biologically active molecule or an...
7115576 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate  
The invention relates to novel pharmaceutical forms for antibiotics containing amino sugar, amphotericin B, daunorubicin and doxorubicin, in which the known side effects are reduced and which can...
7109177 Methods and compositions for the manufacture of C-3′ and C-4′ anthracycline antibiotics  
The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic...
7091188 Stabilization of amrubicin hydrochloride  
A stabilized amrubicin hydrochloride composition which comprises 3 to 8 wt. % water and 92 to 97 wt. % amrubicin hydrochloride; and a method of storing amrubicin hydrochloride.
7053191 Method of preparing 4-R-substituted 4-demethoxydaunorubicin  
A method of synthesizing 4-R-substituted anthracyclines and their corresponding salts from 4-demethyldaunorubicin includes the steps of treating 4-demethyldaunorubicin with a sulfonylating agent to...
7005421 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside  
According to the invention there is provided a sterile, pyrogen-free, ready-to-use solution of an anthracycline glycoside, especially doxorubicin, which consists essentially of a physiologically...
6927211 Method for reducing toxicity of combined chemotherapies  
Compositions and methods are provided for use in the treatment of cancer.
6921841 Process for the synthesis of optically active anthracyclines  
It is described a process for the synthesis of optically active anthracyclines by the fact that the key intermediate (R)2-acetyl-2-hydroxy-1,2,3,4-tetrahydronaphtalene...
6914046 NF-κB activation inhibitors, and their pharmaceutical uses  
Compounds inhibiting the activation of the nuclear factor κB (NF-κB) are used for the preparation of medications adapted for the treatment of malignant hemopathies and solid tumors, and for the...
6844318 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use  
This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to...
6720306 Tetrapartate prodrugs  
A compound of Formula I, providing tetrapartate prodrugs is provided wherein: L 1 is a bifunctional linking moiety; D is a moiety that is a leaving group, or a residue of a compound to be...
6716821 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same  
Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via...
6709679 Antineoplastic conjugates of transferin, albumin and polyethylene glycol  
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at...
6680300 Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents  
The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor...
6677309 Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity compounds, compositions and methods  
Monomeric and dimeric anti-cancer drug aldehyde conjugate compounds and pharmaceutically acceptable salts thereof. Specifically, monomeric and dimeric aldehyde conjugates of 1-2,...
6673907 Methods and compositions for the manufacture of C-3′ and C-4′ anthracycline antibiotics  
The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic...
6670348 Methods and compositions for destruction of selected proteins  
Compounds having an ansamycin anitibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective...
6653455 Crystallization of doxorubicin hydrochloride  
Disclosed are a crystallizing method of doxorubicin hydrochloride from a doxorubicin hydrochloride-containing solution, particularly a method for carrying out the crystallization under a condition...
6653289 L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them  
The present invention refers to compounds of general formula (I), the pharmaceutically acceptable salts thereof, the processes for their preparation, and the pharmaceutical compositions containing...
6630579 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use  
A cytotoxic agent comprising one or more modified doxorubicins/daunorubicin linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a...
6624142 Trimethyl lock based tetrapartate prodrugs  
The invention is directed primarily to compounds of Formula I: wherein: R 1 is a polymeric residue; L 1 is a bifunctional linking group; Y 1 and Y 2 are independently O, S or NR 7 ; R 2-7 ...
6500936 Pluraflavins and derivatives thereof, process for their preparation and use thereof  
The invention relates to a compound of formula (I) wherein R 1 is a sugar; R 2 is —CH 2 —O—(R 7 )m, R 7 representing a sugar, or is —COOH; R 3 is an epoxide-comprising group, or is C...
6433150 Anthracycline analogues bearing latent alkylating substituents  
Compound having the structure where anthracycline, N, R a , X, R b, n and m are as defined in the specification. The compound of the invention is activatable in vivo by esterases and...
6399583 Hybrid anthracyclines from genetically engineered streptomyces galilaeus strains, process for production and uses thereof  
The present invention relates to novel hybrid anthracyclines generated by cloning of fused genes in a mutated Streptomyces galilaeus strain DSM 11638. Said strain was obtained by mutagenization...
6391305 Conjugates useful in the treatment of prostate cancer  
Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking...
6388058 Method of purifying daunomycin  
The present invention relates to a method in which daunomycin is eluted from a hydrophobic porous synthetic resin carrier onto which daunomycin is adsorbed from crude daunomycin with a buffered...
6376469 Crystalline amrubicin hydrochloride  
β-Type crystalline amrubicin hydrochloride having a powder X-ray diffraction pattern having average values of diffraction angle(2θ) and relative intensity as given in the following table: ...
6355784 Methods and compositions for the manufacture of halogenated anthracyclines with increased antitumor activity, other anthracyclines, halogenated sugars, and glycosyl donors  
The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In...
6303569 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents  
The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric compounds comprise the formula: ##STR1## wherein: B is H, OH, OSiR 13 , a...
6284737 Methods of treatment with anthracycline derivatives  
The present invention is a compound having the structure ##STR1## where: anthracycline is doxorubicin, daunorubicin or a derivative thereof; N is the 3' nitrogen of daunosamine; R a is H...
6281342 Pradimicin compounds  
Disclosed are novel pradimicin compounds which possess antifungal activity and, preferably, improved water solubility. The compounds of the invention are prepared by modifying the 4'-amino or...
6258786 13-dihydro-3' aziridino anthracyclines  
The present invention relates to anthracycline glycosides, to a process for their preparation and to pharmaceutical compositions containing the same.
6218519 Compounds and methods for the selective treatment of cancer and bacterial infections  
The present invention relates to compounds containing an anthracyclinone group such as doxorubicin, daunorubicin or a derivative thereof. The compounds of the invention also contain ester,...
6187758 Anthracycline glycosides  
An anthracycline glycoside of formula I ##STR1## wherein R is one of the two following residues: ##STR2## or a pharmaceutically acceptable salt thereof.
6184365 Anthracycline derivatives having 4-amino-2,4,6-trideoxy-2 fluoro-α-L-talopyranosyl group  
7-O-(4-Amino-2,4,6-trideoxy-2-fluoro-α-L-talopyranosyl)-dau nomycinone or -adriamycinone is now synthesized as a novel daunomycinone or adriamycinone derivative having the general formula ##STR1##...
6180095 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents  
The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric prodrugs are preferably of the formula: ##STR1## wherein: L 1 is a bifunctional...
6177404 Conjugates useful in the treatment of benign prostatic hyperplasia  
Novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in...
6160102 Oligonucleotide-anthracycline and oligonucleotide-anthracyclinone conjugates  
The present invention refers to conjugates formed by a natural or modified oligonucleotide, capable of forming a triple helix with a DNA chain, linked to the aglycone moiety of an anthracycline or...
6103700 Fluoro labelled anthracyclinone and anthracycline derivatives  
Compounds of formula (A), wherein R 1 , R 2 , R 3 , Y and Z are organic substituents, are useful in the diagnosis of amyloidosis; some of the compounds of formula (A) are novel. Processes for their...
6080396 Anthracycline compound derivative and pharmaceutical preparation containing the same  
A dimer, trimer or tetramer of an anthracycline compound which can be obtained by directly, chemically bonding anthracycline compounds having anticancer activities to each other by an alkali...
6075135 3,4-di-O,N-Protected-4-amino-2,4,6-trideoxy-2-fluoro-L-manno-pyranosyl halide and a process for its preparation  
7-O-(4-Amino-2,4,6-trideoxy-2-fluoro-α-L-mannopyranosyl)-da unomycinon e or -adriamycinone is now synthesized as a daunomycinone or adriamycinone derivative having the general formula ##STR1##...
6020316 Glutaraldehyde modified chemotherapeutic agents and methods of use thereof  
Clinical utility of chemotherapy agents is limited by dose-dependent systemic toxicity and emergence of resistant tumor cell lines. The present invention provides derivatives of chemotherapeutic...
Matches 1 - 50 out of 309 1 2 3 4 5 6 7 >